TSLP and chronic rhinosinusitis with nasal polyps: A multicenter Phase Ib/IIa clinical study for subjects with uncontrolled CRSwNP (DUBHE) was conducted to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of another anti-TSLP monoclonal antibody, CM326 [59].